Activation of G protein-coupled receptors (GPCRs)2 results in stimulation of ERK 1/2, two members of the family of MAPKs implicated in cell growth, differentiation, and proliferation (1). The intracellular pathways mediating ERK1/2 stimulation include transactivation of receptor tyrosine kinases (RTK), e.g. the epidermal growth factor (EGF) receptor, which integrates a number of different GPCR-derived signals to activation of the well conserved Ras/Raf-1/ERK1/2 signal transduction module (2). Generally, the duration of ERK1/2 signaling by GPCRs is transient and desensitizes rapidly within minutes after receptor stimulation (3). This time course is best demonstrated for ␦-opioid receptor (DOR) carrying cell lines and tissues, in which a number of full opioid agonists, like the alkaloid etorphine and the opioid peptide [D-Pen 2,5 ]enkephalin, produce short term stimulation of ERK1/2 signaling that peaks after 5 min and completely reverts to control levels within 60 min of receptor stimulation (4, 5). Desensitization of GPCRinduced mitogenic signaling is mediated by degradation rather than phosphorylation and internalization of transactivated RTKs, because endocytosed EGF receptors are still able to mediate ERK1/2 activation (6, 7). Besides the induction of transient mitogenic signaling, the DOR system is also characterized by the ability of morphine to induce long lasting stimulation of the ERK1/2 pathway (8). Because stimulation of ERK1/2 activity by morphine is also mediated by transactivation of EGF receptors (4), it might be speculated that the ligand-specific property of morphine to produce persistent ERK1/2 stimulation is mediated by its failure to desensitize RTK signaling.Morphine, a partial alkaloid agonist, differs from other opioids because it fails to induce opioid receptor desensitization and internalization (9). As a consequence, chronic morphine treatment is associated with a number of compensatory adaptations on a post-receptor level, including quantitative and qualitative changes in G proteins (10), effectors (11), and regulators of GPCR sensitivity (12, 13). Among the latter, protein kinase A-and protein kinase C-mediated phosphorylation of G subunits, adenylyl cyclase type II, and G protein-coupled receptor kinase 2 (GRK2) has been shown to enhance opioid receptor signaling (12,14). In addition, chronic morphine treatment also results in inhibition of -arrestin1 function, an adapter protein that plays a central role in receptor sequestration and endocytosis. Because the -arrestin1-dependent pathway is not specific for a certain receptor, chronic morphine treatment not only results in attenuation of homologous desensitization but also of heterologous desensitization of other inhibitory GPCRs, like the CB1 cannabinoid and M 4 muscarinic receptor (8). Besides their role in GPCR signaling, -arrestin1, GRK2, and G␥ subunits have also been shown to regulate